Remote patient monitoring and behaviour and lifestyle modification categories of digital diabetes management solutions fail to yield significant clinical advantages and instead escalate healthcare expenditures compared to conventional care, a report by Peterson Health Technology Institute (PHTI), has found . Evidence indicates that enhancements in glycemic control among users of these solutions are marginal and short-lived.
Upon factoring in the typical cost of these products, they contribute to a rise in overall healthcare spending for buyers as the modest projected savings fall short of covering the expense of the solution. Notable exceptions may apply to individuals with initially high HbA1c levels commencing insulin therapy and those pursuing diabetes remission via nutritional ketosis.
These conclusions adhere to the standards outlined in the ICER-PHTI Assessment Framework and the currently accessible data. PHTI conducted a supplementary research review based on existing literature and resources, without undertaking original tool testing.
Click here to read the original news story.